Article

Moderate glaucoma best served by aggressive IOP-lowering efforts

London-The Early Manifest Glaucoma Trial (EMGT) provides a unique set of data for the natural history of moderate glaucoma and demonstrates that lowering IOP by 25% protects against progression of visual field loss, according to Roger A. Hitchings, MD.

Related Videos
2 experts are featured in this series.
Image credit: ©Ophthalmology Times
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Wendy Lee, MD, talks about functional oculoplastics and aesthetics at EnVision Summit 2025
1 expert is featured in this series.
Lana Rifkin, MD, uveitis committee chair at EnVision Summit 2025
Related Content
RhyGaze secures Series A financing of $86 million to further novel gene therapy
January 15th 2025

RhyGaze secures Series A financing of $86 million to further novel gene therapy

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Ocugen announces positive 2-year safety and efficacy update of Phase 1/2 OCU400 for treatment of retinitis pigmentosa
January 15th 2025

Ocugen announces positive 2-year safety and efficacy update of Phase 1/2 OCU400 for treatment of retinitis pigmentosa

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Samsara Vision announces positive intermediate-term visual and safety outcomes of SING IMT 6 months post-surgery
January 14th 2025

Samsara Vision announces positive intermediate-term visual and safety outcomes of SING IMT 6 months post-surgery

4DMT refocuses pipeline to prioritize 4D-150 trials in wet AMD and DME
January 13th 2025

4DMT refocuses pipeline to prioritize 4D-150 trials in wet AMD and DME

© 2025 MJH Life Sciences

All rights reserved.